Boston Scientific (BSX)
Technical, fundamental, and sentiment analysis with recent related videos.
BSX rates Neutral overall. The fundamental read is bullish: the company passes 6 of 9 quality tests on the Piotroski F-Score; balance sheet is in the Safe zone (Altman Z = 3.07); revenue is growing about 16.6% per year; net income is growing about 66.9% per year. The technical picture is bearish: price is 20.8% below the 200-day moving average; 0.4% above the 50-day; the 50/200 relationship is in a Death cross. Sentiment is bearish (composite 45/100), based on 5 news articles from recent coverage.
Revenue 3-year avg +16.6%. Net income 3-year avg +66.9%.
Price vs 20DMA +4.1%. RSI 56.51. Bollinger state: Inside Bands.
Composite score 45/100 from the AI judge, based on 5 news items, 0 television segments, and 0 videos.
Latest Market Read
Boston Scientific’s badges split. Fundamentals are Bullish: revenue averaged 16.6 percent per year and net income averaged 66.9 percent per year over three years, so growth drives that label. Technical is Bearish: price sits about 20.8 percent below the 200-day average and, despite being 4.1 percent above its 20-day moving average (the average close over the last 20 trading days) and the Relative Strength Index (RSI, a momentum reading) at 56.5, the longer-term trend stays negative. Sentiment’s composite is 45/100, which sits in the Neutral band even though coverage leans cautious. The three signals net to an Overall Neutral rating.
Recent news: Global Database of Events, Language, and Tone (GDELT) coverage and Internet Archive TV clips focused on Boston Scientific’s softer 2026 to 2027 guidance and the stock’s 54.8 percent year-over-year (YoY) decline, while filings show Sterling Capital and Murphy Pohlad buying shares. ResearchAndMarkets highlighted pacemaker market growth and named Boston Scientific a key player. Recent videos also flagged a cyberattack story that briefly pressured the shares.